Compare MANU & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MANU | ADPT |
|---|---|---|
| Founded | 1878 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2012 | 2019 |
| Metric | MANU | ADPT |
|---|---|---|
| Price | $17.36 | $15.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $17.78 |
| AVG Volume (30 Days) | 302.6K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $178,957,000.00 |
| Revenue This Year | $0.01 | $3.98 |
| Revenue Next Year | $15.68 | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.10 |
| 52 Week Low | $12.05 | $6.26 |
| 52 Week High | $18.94 | $20.76 |
| Indicator | MANU | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 43.95 |
| Support Level | $16.75 | $14.91 |
| Resistance Level | $18.08 | $17.91 |
| Average True Range (ATR) | 0.49 | 1.02 |
| MACD | -0.05 | -0.11 |
| Stochastic Oscillator | 50.90 | 30.41 |
Manchester United PLC operates as a professional football club with related activities, generating revenue prominently through commercial, broadcasting, and matchday segments. The commercial segment monetizes the various brands via sponsorships, retail, merchandising, apparel, and product licensing. Broadcasting revenue comes from television rights linked to football leagues and competitions, alongside content delivered through its dedicated TV channel all over the globe. Matchday income includes ticket sales, hospitality, merchandise, and services at its stadium. Manchester United is based in England. The company's operations and fan base extends to many countries, supporting a diversified revenue model based on brand engagement and football-related content.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).